Treating the whole patient for optimal management of type 2 diabetes: Considerations for insulin therapy

Southern Medical Journal

Volumn 100, Issue 8, 2007, Pages 804-811

  Campos, Carlos ^a,b  

^a Institute for Public Health and Education Research Inc   (United States)

^b NONE   (United States)

Author keywords

Combination therapy; Diabetes management; Insulin; Treatment barriers

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN;

CARDIOVASCULAR DISEASE; COMORBIDITY; DISEASE COURSE; ETHNICITY; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT EDUCATION; REVIEW; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; LIFE STYLE; OBESITY; PHYSICIANS, FAMILY; RISK FACTORS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 34548457243     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3180485a9d     Document Type: Review

References (50)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
2. American Diabetes Association. Diabetes statistics for African Americans. Available at: http://www.diabetes.org/diabetes-statistics/african-american.jsp. Accessed April 8, 2007.
3. Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev 2002;18(suppl 3):S21-S26.
4. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005;146:693-700.
5. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289:2254-2264.
6. Gæde P, Pedersen O. Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: what are we waiting for? Horm Metab Res 2005;37(suppl 1):76-82.
7. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, et al (eds). Diabetes in America. 2nd ed. Washington, DC, National Institutes of Health, 1995: pp. 429-448.
8. American Association of Clinical Endocrinologists. State of diabetes in America [press release] Available at: http://www.aace.com/newsroom/press/2005/ index.php?r=20050510. Accessed April 8, 2007.
9. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342.
10. American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care 2006;29(suppl 1):S4-S42.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
12. Harris MI, Klein R, Cowie CC, et al. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A US population study. Diabetes Care 1998;21:1230-1235.
13. Hamman RF, Marshall JA, Baxter J, et al. Methods and prevalence of non-insulin-dependent diabetes mellitus in a biethnic Colorado population: the San Luis Valley Diabetes Study. Am J Epidemiol 1989;129:295-311.
14. Hamman RF, Franklin GA, Mayer EJ, et al. Microvascular complications of NIDDM in Hispanics and non-Hispanic whites: San Luis Valley Diabetes Study. Diabetes Care 1991;14:655-664.
15. Cruickshank JK, Alleyne SA. Black West Indian and matched white diabetics in Britain compared with diabetics in Jamaica: body mass, blood pressure, and vascular disease. Diabetes Care 1987;10:170-179.
16. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-S36.
17. Rohlfing CL, Wiedmeyer H-M, Little RR, et al. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278.
18. Dailey G. A timely transition to insulin: identifying type 2 diabetes patients failing oral therapy. Formulary 2005;40:114-130.
19. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-372.
20. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
21. Willett LL, Albright ES. Achieving glycemic control in type 2 diabetes: a practical guide for clinicians on oral hypoglycemics. South Med J 2004;97:1088-1092.
22. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012.
23. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258.
24. Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-336.
25. Yale J-F, Valiquett TR, Ghazzi MN, et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:737-745.
26. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-183.
27. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569.
28. Carroll MF, Izard A, Riboni K, et al. Fasting hyperglycemia predicts the magnitude of postprandial hyperglycemia: implications for diabetes therapy. Diabetes Care 2002;25:1247-1248.
29. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-2148.
30. Fritsche A, Schweitzer MA, Häring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2003;138:952-959.
31. Yki-Järvinen H, Dressler A, Ziemen M. HOE 901/3002 Study Group: less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.
32. Rašlová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.
33. Riddle MC, Rosenstock J, Gerich J, et al, on behalf of the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
34. Ryysy L, Yki-Järvinen H, Hänninen J. Simplifying treat to target - the LANMET study. In: Program and abstracts of the 40th European Association for the Study of Diabetes Annual Meeting. September 5-9, 2004; Munich, Germany. Abstract 749.
35. Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-196.
36. Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-636.
37. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-1659.
38. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26:881-885.
39. Dailey G, Rosenstock J, Moses R, et al. Glycemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with type 2 diabetes. In: Program and Abstracts of the American Diabetes Association 64th Annual Scientific Sessions. June 4-8, 2004; Orlando, FL.
40. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 1997;20:292-298.
41. Meneghini LF, Wick AK, Delamater AM, et al. Group-based self-management intervention for intensification of insulin therapy. In: Program and Abstracts of the American Diabetes Association 63rd Annual Scientific Sessions. June 13-17, 2003; New Orleans, LA. Abstract 131-OR.
42. American Diabetes Association. Por tu familia: la diabetes y los latinos. Available at: http://www.portufamilia.org. Accessed April 8, 2007.
43. Heuer L, Hess CW, Klug MG. Meeting the health care needs of a rural Hispanic migrant population with diabetes. J Rural Health 2004;20:265-270.
44. TIPHER: The Institute for Public Health and Education Research. Available at: http://www.tipher.com/index.htm. Accessed April 8, 2007.
45. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocr Pract 2002;8(suppl 1):5-11.
46. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
47. National Cholesterol Education Program. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. Washington, DC: US Department of Health and Human Services, National Institutes of Health. September 2002. NIH Publication No. 02-5215.
48. Levemir [package insert]. Princeton, Novo Nordisk Inc, 2005.
49. Apidra [package insert]. Kansas City, Aventis Pharmaceuticals Inc, 2004.
50. Exubera [package insert]. New York, Pfizer Inc, 2006.